Mainz, Germany and Mumbai, India, August 9th, 2017
- Strategic partnership to make BioNTech´s mRNA-based molecular breast cancer stratification test, MammaTyper®, commercially available in India, Sri Lanka, Kenya, Mauritius, Ghana and Zambia through Metropolis’ medical testing service laboratorie
- Partners combine their expertise in in vitro diagnostics and clinical testing services to enable precise characterization of breast cancer tumor types
- BioNTech Diagnostics GmbH, a fully-
owned subsidiary of BioNTech AG, a company pioneering individualized cancer immunotherapy and diagnostics, and Metropolis Healthcare Ltd., India’s leading chain of pathology labs and diagnostics centers announced today their strategic partnership to offer breast cancer stratification testing in India, Sri Lanka, Kenya, Mauritius, Ghana and Zambia. Metropolis will provide access to BioNTech’s MammaTyper® test through its laboratory testing services. With a population of more than one billion people and 144,000 newly detected breast cancer cases per year, India is in dire need of innovative diagnostic tests that improve treatment outcomes.
"We are very pleased to enter this partnership with Metropolis, one of the most respected medical testing labs in India, allowing access to MammaTyper® in one of the largest regions in the world," said Dr. Sierk Poetting, Managing Director BioNTech Diagnostics GmbH. "With its onco-pathological expertise and strong presence in six countries, Metropolis is well suited to help address the significant patient need that exists while also enabling market reach to inform continued growth."
"This alliance reinforces Metropolis’ strategy to offer innovative tests, which combine proven medical markers with the newest measurement technology, to provide trusted results to patients and clinicians," stated Ms. Ameera Shah, Managing Director of Metropolis Healthcare Ltd. "We are delighted to offer MammaTyper® in our testing service in partnership with BioNTech. "
MammaTyper® is a CE/IVD ...
International multicenter study in ten pathology laboratories in the U.S., Canada, Europe and Asia MammaTyper® provides highly reproducible quantitative results of the mRNA expression status of the four biomarkers HER2 (ERBB2), ER (ESR1), PR (PGR) and Ki-67 (MKI67) Mainz, May 15, 2017: BioNTech Diagnostics GmbH today announced the publication of an international prospective multicenter study …
First comparison of a biomarker analysis by RT-qPCR (MammaTyper®) versus visual or computer-assisted immunohistochemistry (IHC) in subtyping mammary carcinomas Significantly more precise prediction of pathologically complete remission in a neoadjuvant setting with MammaTyper® compared to manual or computer-assisted IHC; better therapy stratification and possible avoidance of unnecessary therapies MammaTyper® provides reliable quantitative determination of MKI67-mRNA …
Mainz, Germany and Deqing, China, August 19, 2016 — BioNTech Diagnostics GmbH, a fully owned subsidiary of BioNTech AG, and its Chinese partner Shuwen Biotech Co. Ltd. today announced that the Chinese FDA (CFDA) has granted the “Innovative Medical Product” status for MammaTyper®, a real-time PCR kit for breast cancer stratification. This diagnostic product will …
Mainz, Germany, July 12, 2016: BioNTech Diagnostics GmbH announces the publication of new study data which confirms the high analytical performance of the in vitro diagnostic test kit MammaTyper® (CE labeled IVD) in breast cancer subtyping . MammaTyper® allows a precise quantitative determination of the mRNA expression of the biomarkers ERBB2 (HER2), ESR1 (ER), PGR …